Medical Innovation Exchange

In wake of bempeg blowup, Sanofi rethinks $2.5B bet on IL-2 after midphase efficacy falls short

https://www.fiercebiotech.com/biotech/wake-bempeg-blowup-sanofi-rethinks-25b-bet-il-2-after-midphase-efficacy-falls-short

Leave a Comment

Your email address will not be published. Required fields are marked *

Leave the field below empty!